Revenue of top 20 respiratory brands in the U.S. 2016
This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.
Top respiratory products
Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.
Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
Top respiratory products
Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.
Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
